Salarius Pharmaceuticals is rebranding to Decoy Therapeutics and changing its Nasdaq ticker symbol to DCOY.
The company focuses on developing next-generation peptide-conjugate therapeutics.
Trading under the new ticker symbol DCOY will commence on January 8, 2026.
Focused Direction
Decoy Therapeutics aims to develop novel peptide-conjugate therapeutics with an initial emphasis on viral and oncology targets.
AI Integration
The company leverages AI-enabled computational infrastructure to accelerate candidate selection.
Strategic Partnerships
Decoy is pursuing collaborations with global health organizations and potential future partners for development opportunities.
- Decoy Therapeutics' platform is designed to selectively intercept and neutralize high-value biological targets.
- The company's lead antiviral program has attracted interest from strategic organizations such as BARDA and global health stakeholders.
The rebranding of Salarius Pharmaceuticals to Decoy Therapeutics marks a strategic shift towards innovative peptide-conjugate therapeutics, showcasing a focused 2026 plan and potential partnerships for the future.